InvestorsHub Logo
Followers 6
Posts 968
Boards Moderated 0
Alias Born 02/26/2016

Re: None

Friday, 12/04/2020 10:28:45 AM

Friday, December 04, 2020 10:28:45 AM

Post# of 5070
Zack Report just came out: BCRX deep pipeline, to me is the single key statement in the report.

https://finance.yahoo.com/news/biocryst-bcrx-wins-fda-approval-140002117.html

Key take away:
BCRX, the company has a deep pipeline with several ongoing development programs that includes BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever; and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BCRX News